RE: Fast Track Designation Granted for Brepocitinib24 Sep 2024 18:57
Damon. These figures are why I think some here have there figures skewed. Regardless of how it is funded, If we start p2a eg we get approval etc, then the 500 to 800 million dollars quoted, should be the low ball offer, and we have 2 compounds. If it were buy one get one half price we shouldn't be settling for any less than 750 million dollars or 560 million pounds. If you add 737 Into this then £7 per share still sounds cheap. We just need to start p2a and hope it progresses well.